Presenter: Jud Kimmel, Neuroendocrine Cancer Patient / Advocate
Date: Wednesday, March 25, 2026
Time: 3:30pm – 4:30pm EDT
After more than a year of worsening symptoms and inconclusive tests, Jud Kimmel was diagnosed in September 2022 with Stage IV, Grade 3 Small Bowel Neuroendocrine Tumor (NET). He received Lu-177 Dotatate as a first-line treatment through the NETTER-2 clinical trial, which significantly reduced his disease burden. This response enabled surgeons to perform a total tumor resection and ablation of the 25 visible NETs in his small bowel, mesentery, and liver.
Although Stage IV NET is considered incurable, Jud currently has NEAD (no evidence of active disease) and uses this time to educate and support other cancer patients—particularly on topics related to nuclear medicine and molecular imaging. Jud lives in Saint Paul, Minnesota, with his wife and one of their three children who is still at home.
In this session, Jud will help you to:
- understand psychological challenges common to today’s cancer patient – that is, with unlimited access to medical information, including their own records.
- learn how these challenges are a foundation upon which prospective and actual RLT patients then develop several RLT-specific concerns and perceptions.
- discuss concrete ways to enhance provider – patient communication and trust around radioligand therapies and theranostics more generally.
Approved for 1.0 CEH credit from SNMMI.